Precision Oncology Testing in 2023: Time to Go Big?

Colin C. Pritchard, MD, PhD
Professor; Co-Director, Genetics and Solid Tumors Laboratory 
Department of Laboratory Medicine and Pathology
University of Washington 
Program Director for Cancer Precision Diagnostics, Brotman Baty Institute for Precision Medicine 

Why Attend this Seminar? 

Precision oncology is here, and many cancer patients are benefiting from this new paradigm.  Next generation sequencing (NGS) has enabled increasingly sophisticated cancer tests for tumor profiling to guide treatment and for assessment of inherited cancer risk.  In this presentation, I will focus on clinical applications of NGS in oncology in 2023, particularly on DNA repair pathways that are important for both treatment and familial risk. I will explore the relationship between somatic (tumor) and germline (inherited) findings, as well as the intersection between NGS, digital pathology, and AI.  The talk will cover what will be needed to continue to expand precision oncology testing services in order to meet the rapidly growing clinical demand.

Meeting ID: 930 4620 8772
Passcode: PATH520